MedPath
HSA Product

Volulyte Solution for Infusion 6%

Product approved by Health Sciences Authority (SG)

Basic Information

Volulyte Solution for Infusion 6%

INFUSION, SOLUTION

Regulatory Information

SIN13893P

December 2, 2010

General Sale List

Therapeutic

INTRAVENOUS

August 10, 2023

June 3, 2025

Company Information

FRESENIUS KABI (SINGAPORE) PTE LTD

FRESENIUS KABI (SINGAPORE) PTE LTD

Active Ingredients

Detailed Information

Contraindications

**4.3 Contraindications** Do not use HES products in: - patients with known hypersensitivity to hydroxyethyl starch - patients with sepsis - patients with renal failure with oliguria or anuria not related to hypovolaemia - patients receiving dialysis treatment - patients with intracranial bleeding - clinical conditions where volume overload (hyperhydration) is a potential problem, especially in cases of pulmonary oedema and congestive cardiac failure - patients with severe hyperkalaemia, severe hypernatraemia or severe hyperchloraemia - patients with severe liver disease - patients with pre-existing coagulation or bleeding disorders

Indication Information

**4.1 Therapeutic indications** Volulyte is indicated for the treatment and prophylaxis of hypovolaemia in adults and children. It is not a substitute for red blood cells or coagulation factors in plasma.

© Copyright 2025. All Rights Reserved by MedPath